# Amlitelimab PDUFA date and FDA approval status

Canonical: https://sec-api.dev/pdufa/amlitelimab

> The next catalyst for amlitelimab, sponsored by Sanofi (SNY), is its topline data readout, Sep to Dec 2027.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Key facts

| Field | Value |
| --- | --- |
| Drug | amlitelimab |
| Codes | SAR445229 |
| Sponsor | Sanofi (SNY) https://sec-api.dev/companies/sny/catalysts |
| Indications | Coeliac Disease, [Dermatitis Atopic](https://sec-api.dev/indications/dermatitis-atopic), [Alopecia Areata](https://sec-api.dev/indications/alopecia-areata), [Asthma](https://sec-api.dev/indications/asthma) |
| Modality | antibody |
| FDA designations | none disclosed |

## Timeline

### July 23, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Dermatitis Atopic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06130566 (A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-07-23 (ACTUAL); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06130566

### August 21, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Dermatitis Atopic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06224348 (A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-08-21 (ACTUAL); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06224348

### September 24, 2025: primary completion

- Status: withdrawn. Date confidence: exact. Stage: 2. Indication: Alopecia Areata.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06444451 (A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Adult Participants With Severe Alopecia Areata): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2025-09-24 (ACTUAL); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06444451

### October 1, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Dermatitis Atopic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06015308 (A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo): Overall Status COMPLETED; Phase PHASE2; Primary Completion 2025-10-01 (ACTUAL); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06015308

### November 25, 2025: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Dermatitis Atopic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06181435 (A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)): Overall Status COMPLETED; Phase PHASE3; Primary Completion 2025-11-25 (ACTUAL); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06181435

### June 10, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 3. Indication: Dermatitis Atopic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06407934 (A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-06-10 (ACTUAL); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06407934

### August 5, 2026: primary completion

- Status: completed. Date confidence: exact. Stage: 2. Indication: Coeliac Disease; Celiac Disease.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06557772 (A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-08-05 (ACTUAL); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06557772

### Aug to Nov 2026: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2. Indication: Coeliac Disease; Celiac Disease.
- First seen 2026-07-27, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06557772 (A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2; Primary Completion 2026-08-05 (ACTUAL); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06557772
- Press release filed with the SEC (EX-99) (accession 0001193125-26-316771): "The phase 2 study of amlitelimab in celiac disease is ongoing and expected to readout in the second half of 2026." https://www.sec.gov/Archives/edgar/data/1121404/000119312526316771/d150377dex992.htm

### September 22, 2026: primary completion

- Status: withdrawn. Date confidence: exact. Stage: 2. Indication: Asthma.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06033833 (Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study): Overall Status TERMINATED; Phase PHASE2; Primary Completion 2026-09-22 (ACTUAL); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06033833

### Sep to Dec 2027: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 3. Indication: Dermatitis Atopic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06241118 (A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06241118

### September 2027: primary completion

- Status: scheduled. Date confidence: month. Stage: 3. Indication: Dermatitis Atopic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT06241118 (A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab on Background Topical Corticosteroids Therapy in Participants Aged 12 Years and Older With Moderate-to-severe AD Who Have Had an Inadequate Response to Prior Biologic Therapy or an Oral JAK Inhibitor): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-09-30 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT06241118

### Jan to Apr 2029: topline data readout

- Status: scheduled. Date confidence: quarter. Stage: 2/3. Indication: Dermatitis Atopic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05492578 (Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-01-22 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT05492578

### January 2029: primary completion

- Status: scheduled. Date confidence: month. Stage: 2/3. Indication: Dermatitis Atopic.
- First seen 2026-11-12T03:44:55.771Z, last confirmed 2026-11-16T22:20:01.192Z.
- ClinicalTrials.gov: "NCT05492578 (Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE2, PHASE3; Primary Completion 2029-01-22 (ESTIMATED); Lead Sponsor Sanofi." https://clinicaltrials.gov/study/NCT05492578

## Same indication

- [Aro-rage](https://sec-api.dev/pdufa/aro-rage) (ARWR)
- [Atuliflapon](https://sec-api.dev/pdufa/atuliflapon) (AZN)
- [AZD4604](https://sec-api.dev/pdufa/azd4604) (AZN)
- [AZD8630](https://sec-api.dev/pdufa/azd8630) (AZN)
- [Bda mdi](https://sec-api.dev/pdufa/bda-mdi) (AZN)
- [Bda mdi hfo 160/180 μg](https://sec-api.dev/pdufa/bda-mdi-hfo-160) (AZN)
- [Bempikibart (adx-914)](https://sec-api.dev/pdufa/bempikibart-adx-914) (QTTB)
- [Fasenra (benralizumab)](https://sec-api.dev/pdufa/benralizumab) (AZN)
- [Bff mdi](https://sec-api.dev/pdufa/bff-mdi) (AZN)
- [Brenipatide](https://sec-api.dev/pdufa/brenipatide) (LLY)
- [Budesonide/albuterol metered dose inhaler, mdi](https://sec-api.dev/pdufa/budesonide-albuterol-metered-dose-inhaler-mdi) (AZN)
- [Depemokimab](https://sec-api.dev/pdufa/depemokimab) (GSK)
- [Dupilumab coformulated with berahyaluronidase alfa](https://sec-api.dev/pdufa/dupilumab-coformulated-with-berahyaluronidase-alfa) (SNY)
- [Ff/umec/vi](https://sec-api.dev/pdufa/ff-umec-vi) (GSK)
- [Fp/abs](https://sec-api.dev/pdufa/fp-abs) (TEVA)
- [Qbrexza (glycopyrronium tosylate)](https://sec-api.dev/pdufa/glycopyrronium) (DERM)
- [Gp mdi](https://sec-api.dev/pdufa/gp-mdi) (AZN)
- [Gsk3511294 (depemokimab)](https://sec-api.dev/pdufa/gsk3511294-depemokimab) (GSK)
- [GSK5784283](https://sec-api.dev/pdufa/gsk5784283) (GSK)
- [HFA-152A](https://sec-api.dev/pdufa/hfa-152a) (GSK)
- [Intervention: as mdi](https://sec-api.dev/pdufa/intervention-as-mdi) (AZN)
- [JNJ-95597528](https://sec-api.dev/pdufa/jnj-95597528) (JNJ)
- [Londamocitinib](https://sec-api.dev/pdufa/londamocitinib) (AZN)
- [Lunsekimig](https://sec-api.dev/pdufa/lunsekimig) (SNY)
- [LY4005130](https://sec-api.dev/pdufa/ly4005130) (LLY)
- [Nucala (mepolizumab)](https://sec-api.dev/pdufa/mepolizumab) (GSK)
- [Pf-07275315 dose 1](https://sec-api.dev/pdufa/pf-07275315) (PFE)
- [QMF149](https://sec-api.dev/pdufa/qmf149) (NVS)
- [QVM149](https://sec-api.dev/pdufa/qvm149) (NVS)
- [Rezpegaldesleukin](https://sec-api.dev/pdufa/rezpegaldesleukin) (NKTR)
- [Litfulo (ritlecitinib tosylate)](https://sec-api.dev/pdufa/ritlecitinib) (PFE)
- [Rocatinlimab](https://sec-api.dev/pdufa/rocatinlimab) (AMGN)
- [Salbutamol hfa-134a](https://sec-api.dev/pdufa/salbutamol-hfa-134a) (GSK)
- [TEV-56248](https://sec-api.dev/pdufa/tev-56248) (TEVA)
- [TEZSPIRE® (tezepelumab)](https://sec-api.dev/pdufa/tezepelumab) (AZN)
- [Tilrekimig](https://sec-api.dev/pdufa/tilrekimig) (PFE)
- [Tozorakimab](https://sec-api.dev/pdufa/tozorakimab) (AZN)
- [RINVOQ® (upadacitinib)](https://sec-api.dev/pdufa/upadacitinib) (ABBV)
- [WIN378](https://sec-api.dev/pdufa/win378) (WWB)

Calendar months: [September 2027](https://sec-api.dev/fda-calendar/2027-09)

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/pdufa/amlitelimab.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "Amlitelimab PDUFA date and FDA approval status." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/pdufa/amlitelimab

```bibtex
@misc{secapidev_pdufa_amlitelimab_20261116,
  title        = {Amlitelimab PDUFA date and FDA approval status},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/pdufa/amlitelimab}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_pdufa_amlitelimab_20261116","title":"Amlitelimab PDUFA date and FDA approval status","publisher":"sec-api.dev","URL":"https://sec-api.dev/pdufa/amlitelimab","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
